



RECEIVED

MAY 02 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Masamichi OKADA, et al.

Appln. No.: 09/601,505

Confirmation No.: Unassigned

Group Art Unit: 1614

Filed: August 2, 2000

Examiner: FAY, Z

For: REMEDIES FOR CEREBRAL INFARCTION

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Amendment is responsive to the Office Action mailed January 29, 2001, making a response to the Office Action due on or before April 29, 2001. Because April 29, 2001, falls on a Sunday, the due date is extended to Monday, April 30, 2001. This response is therefore timely.

Kindly amend the application as follows:

IN THE SPECIFICATION:

Please replace the paragraph encompassed by page 2, line 25, through page 3, line 4, with the following paragraph:

Though metabotropic glutamate receptors appear to be a significant component in the cascades following excessive glutamate release during and after cerebral ischemia, their roles are not yet clear. Particularly, as the activation of mGluR1 and mGluR5 which is coupled to intracellular IP3 system increases intracellular calcium (Nature, 383, 89-92 1996), continuous excess stimulation of these receptors may cause neuronal cell death.

#7/B
JRP
5/3/01

Sub
B'